Bone health in cancer patients: ESMO Clinical Practice Guidelines.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu103PMID 24782453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

  2014cited by this paper
• Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

  2014cited by this paper
• Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

  2013cited by this paper
• The metastatic microenvironment of breast cancer: clinical implications.

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Pain outcomes in patients with advanced breast cancer and bone metastases

  2013cited by this paper
• Management of cancer treatment-induced bone loss

  2013cited by this paper
• Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

  2013cited by this paper
• Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

  2013cited by this paper
• Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials

  2013cited by this paper
• Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.

  2013cited by this paper
• The Metastatic Microenvironment

  2013cited by this paper
• Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series

  2013cited by this paper
• International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

  2013cited by this paper
• The Role of Denosumab for Prevention of Skeletal-Related Complications in Multiple Myeloma

  2013cited by this paper
• A review of recently published radiotherapy treatment guidelines for bone metastases: Contrasts or convergence?

  2012cited by this paper
• Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

  2012cited by this paper
• Denosumab in patients with cancer—a surgical strike against the osteoclast

  2012cited by this paper
• Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

  2012cited by this paper
• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

  2012cited by this paper
• Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases.

  2012cited by this paper
• Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis.

  2012cited by this paper
• Effects of bone-targeted agents on cancer progression and mortality.

  2012cited by this paper
• Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

  2012cited by this paper
• Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

  2012cited by this paper
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

  2012cited by this paper
• Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.

  2012cited by this paper
• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

  2012cited by this paper
• Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

  2012cited by this paper
• Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.

  2012cited by this paper
• Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab.

  2012cited by this paper
• Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007)

  2011cited by this paper
• Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

  2011cited by this paper
• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

  2011cited by this paper
• Radioisotopes for metastatic bone pain.

  2011cited by this paper
• GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

  2011cited by this paper
• Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

  2011cited by this paper
• Cancer to bone: a fatal attraction

  2011cited by this paper
• Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

  2011cited by this paper
• American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

  2011cited by this paper
• S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer.

  2011cited by this paper
• Bisphosphonates in oncology.

  2011cited by this paper
• Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

  2011cited by this paper
• Consensus on the utility of bone markers in the malignant bone disease setting.

  2011cited by this paper
• Breast-cancer adjuvant therapy with zoledronic acid.

  2011cited by this paper
• Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011influential reference
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  2011cited by this paper
• A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

  2011influential reference
• Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

  2011cited by this paper
• Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review

  2011cited by this paper
• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  2010cited by this paper
• Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

  2010cited by this paper
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  2010cited by this paper
• Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

  2010cited by this paper
• The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

  2010cited by this paper
• Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST

  2010cited by this paper
• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

  2010cited by this paper
• Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.

  2009cited by this paper
• The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

  2009cited by this paper
• The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men.

  2009cited by this paper
• Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

  2008cited by this paper
• Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

  2008cited by this paper
• FRAX™ and the assessment of fracture probability in men and women from the UK

  2008cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

  2008influential reference
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.

  2007cited by this paper
• Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

  2007cited by this paper
• Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club

  2007cited by this paper
• Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

  2007cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

  2007influential reference
• Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

  2006cited by this paper
• Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

  2006cited by this paper
• A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

  2006cited by this paper
• Preparing the "soil": the premetastatic niche.

  2006cited by this paper
• Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

  2006cited by this paper
• Bone quality--the material and structural basis of bone strength and fragility.

  2006cited by this paper
• The role of external beam radiotherapy in the management of bone metastases.

  2006cited by this paper
• Multistate Analysis of Skeletal Events in Patients with Bone Metastases

  2006cited by this paper
• Clinical use of markers of bone turnover in metastatic bone disease

  2005cited by this paper
• Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

  2005cited by this paper
• Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Fracture Risk With Multiple Myeloma: A Population‐Based Study

  2004cited by this paper
• Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

  2004cited by this paper
• Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

  2004cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

  2003cited by this paper
• Radioisotopes for metastatic bone pain.

  2003cited by this paper
• Bisphosphonates for the relief of pain secondary to bone metastases.

  2002cited by this paper
• Bisphosphonates in multiple myeloma.

  2002cited by this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cited by this paper
• Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.

  2001cited by this paper
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  2001cited by this paper

• Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy

  2026cites this paper
• Pancreatic Adenocarcinoma Presenting as a Pathologic Femoral Fracture: A Rare Initial Manifestation

  2026cites this paper
• A pan-cancer single-cell transcriptomic atlas of human bone metastases.

  2026cites this paper
• Efficacy, safety and economy of denosumab and zoledronic acid in the treatment of bone metastases of solid tumors and multiple myeloma: a systematic review and meta-analysis

  2026cites this paper
• Radiation dose assessment and establishment of diagnostic reference levels for MDP Tc-99m bone scans: A multi-hospital study in Saudi Arabia.

  2025cites this paper
• Medication‐Related Osteonecrosis of the Jaws in Patients on Antiresorptive Medication With Dental Implants. A Scoping Review

  2025cites this paper
• Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions

  2025cites this paper
• MicroRNAs in Breast Cancer Bone Metastasis Formation and Progression: An Overview on Recent Progress in This Research Field

  2025cites this paper
• Efficacy of Denosumab in Managing BMD Loss in Breast Cancer Patients Treated with Aromatase Inhibitors

  2025cites this paper
• Multiparametric spinal MRI for differentiating benign and malignant vertebral compression fractures

  2025cites this paper
• The oxidative stress 3-like protein GsOS3L, substrate of GsSnRK1, enhances salt and cadmium stresses in soybean roots.

  2025cites this paper
• Identification of Bone Metastasis-Related Gene Networks in Lung Cancer: Implications for Bone Metabolism

  2025cites this paper
• Enhancing Spinal Metastasis Detection and Feature Evaluation on Computed Tomography Scans Using Deep‐Learning Systems

  2025cites this paper
• Photo‐Curable Triazinetrione Composites With Tunable Degradation for Fracture Stabilization and Flexible Thin‐Film Applications

  2025cites this paper
• Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• Dual-regulatory miRNAs: master regulators and therapeutic targets in bone-metastatic breast cancer

  2025cites this paper
• Identification of the optimal candidates to benefit from surgery and chemotherapy among elderly female breast cancer patients with bone metastases

  2025cites this paper
• Hip metastasis presenting as anterior knee pain from nasopharyngeal carcinoma: A case report

  2025cites this paper
• Phytol-mixed micelles alleviate dexamethasone-induced osteoporosis in zebrafish: Activation of the MMP3–OPN–MAPK pathway-mediating bone remodeling

  2025cites this paper
• MicroRNAs in bone metastases: mechanisms and research progression

  2025cites this paper
• Vertebral Augmentation for Cancer Patients.

  2025cites this paper
• Denosumab versus zoledronic acid: analgesic and survival impact of an extended treatment regimen beyond 2 years in breast cancer

  2025cites this paper
• [Surgical treatment options for bone metastases].

  2025cites this paper
• Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database

  2025cites this paper
• Surgical treatments of metastatic bone disease of the hip joint: a scoping review protocol

  2025cites this paper
• Exosome tropism and various pathways in lung cancer metastasis

  2025cites this paper
• Bone Health and Osteoporosis Management in the Elderly: A Review of Guidelines and Orthopedic Implications

  2025cites this paper
• Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence

  2024cites this paper
• Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment

  2024cites this paper
• Identification of Osteoporotic Changes of Vertebral Bodies on Computed Tomography Images Based on the Analysis of Groups of Textural Features

  2024cites this paper
• Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis

  2024cites this paper
• Bone complications of cancer treatment.

  2024cites this paper
• Evaluating the Anti-Osteoporotic Potential of Mediterranean Medicinal Plants: A Review of Current Evidence

  2024cites this paper
• Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report.

  2024cites this paper
• YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.

  2024cites this paper
• Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience

  2024cites this paper
• Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers

  2024cites this paper
• Bisphosphonate-related osteonecrosis of the jaw: Is the medication duration related to advanced disease stage?

  2024cites this paper
• Management of Metastatic Spinal Disease - A Practical Approach.

  2024cites this paper
• Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy

  2024cites this paper
• Breast cancer survivorship

  2024cites this paper
• Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health

  2024cites this paper
• The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service

  2024influential citation
• Sequenztherapie des kastrationsresistenten Prostatakarzinoms: Evidenzbasierte klinische Algorithmen

  2024cites this paper
• Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study

  2024cites this paper
• Pre-existing medication-related osteonecrosis of the jaw before dental extraction

  2023cites this paper
• Construction of a prognostic score model for breast cancer based on multi-omics analysis of study on bone metastasis

  2023cites this paper
• TNF-α-induced Inhibition of Protein Myristoylation Via Binding Between NMT1 and Sorbs2 in Osteoblasts

  2023cites this paper
• Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab

  2023influential citation
• Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study

  2023cites this paper
• Golgi-triggered radiation sensitizer retention enhances the efferocytosis and immunotherapy in breast cancer with skeleton metastases

  2023cites this paper
• The composition of the blood microbiota and its relationship to osteoporosis-related clinical parameters

  2023cites this paper
• Exosomal hsa-miR-151a-3p and hsa-miR-877-5p are potential novel biomarkers for predicting bone metastasis in lung cancer

  2023cites this paper
• The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications

  2023cites this paper
• A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab

  2023cites this paper
• THE RELATIONSHIP OF BREAST CANCER, BIOMINERALIZATION DISORDERS AND BONE METASTASES: A BIBLIOGRAPHICAL ANALYSIS

  2023cites this paper
• A novel multifunctional radioprotective strategy using P7C3 as a countermeasure against ionizing radiation-induced bone loss

  2023cites this paper
• Efficacy and safety of CT-guided 125I seed implantation by coplanar template as a salvage therapy for vertebral metastases after failure of external beam radiation therapy: a retrospective study

  2023cites this paper
• Searching for Essential Genes and Targeted Drugs Common to Breast Cancer and Osteoarthritis.

  2023cites this paper
• A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases

  2023cites this paper
• Aromatase Inhibitor Musculoskeletal Syndrome and Bone Loss: a Review of the Current Literature

  2023cites this paper
• Bone Metastases Detection in Patients with Breast Cancer: Does Bone Scintigraphy Add Information to PET/CT?

  2023cites this paper
• Quantitative ultrasound of the calcaneus (QUS): A valuable tool in the identification of patients with non-metastatic prostate cancer requiring screening for osteoporosis

  2023cites this paper
• Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction

  2023cites this paper
• Could conventionally fractionated radiation therapy coupled with stereotactic body radiation therapy improve local control in bone oligometastases?

  2023cites this paper
• Nano-hydroxyapatite radiolabeled with radium dichloride [223Ra] RaCl2 for bone cancer targeted alpha therapy: In vitro assay and radiation effect on the nanostructure.

  2023cites this paper
• Comparison of 99mTc-methylenediphosphonate and 68Ga-BPAMD PET/computed tomography imaging in bone metastasis

  2023cites this paper
• Effect of Nano- and Microzinc Supplementation on the Mineral Composition of Bones of Rats with Induced Mammary Gland Cancer

  2023cites this paper
• How has the field of metastatic breast cancer in bones evolved over the past 22 years?

  2023cites this paper
• Denosumab versus Zoledronic Acid in the Treatment of Bone Metastases in Prostate Cancer

  2023cites this paper
• Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis

  2023cites this paper
• Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital

  2023cites this paper
• Association of Androgen Deprivation Therapy with Osteoporotic Fracture in Patients with Prostate Cancer with Low Tumor Burden Using a Retrospective Population-Based Propensity-Score-Matched Cohort

  2023cites this paper
• Oral health in older adults with cancer

  2023cites this paper
• Beyond Antiresorptive Activity: Risedronate-Based Coordination Complexes To Potentially Treat Osteolytic Metastases.

  2023cites this paper
• Oral health in older adults with cancer Saúde

  2023cites this paper
• Relationship between Osteoporosis Patient Outcomes for women with Breast Cancer

  2023cites this paper
• A Microfluidic Experimental Method for Studying Cell-to-Cell Exosome Delivery–Taking Stem Cell–Tumor Cell Interaction as a Case

  2023cites this paper
• Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.

  2023cites this paper
• Bone metastasis risk and prognosis assessment models for kidney cancer based on machine learning

  2022cites this paper
• Cancer metastasis is related to normal tissue stemness

  2022cites this paper
• Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

  2022cites this paper
• Phytol Suppresses Osteoclast Differentiation and Oxidative Stress through Nrf2/HO-1 Regulation in RANKL-Induced RAW264.7 Cells

  2022cites this paper
• Development and validation of a prognostic nomogram for bone metastasis from lung cancer: A large population-based study

  2022cites this paper
• Management of Long Bones Metastatic Disease: Concepts That We All Know but Not Always Remember

  2022cites this paper
• Bibliometric analysis of the global research development of bone metastases in prostate cancer: A 22-year study

  2022cites this paper
• The impact of obesity, lifestyle factors and health interventions on breast cancer survivors.

  2022cites this paper
• Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

  2022cites this paper
• O-arm-guided percutaneous microwave ablation and cementoplasty for the treatment of pelvic acetabulum bone metastasis

  2022cites this paper
• Fragilité osseuse due au traitement du cancer du sein : rôle essentiel des infirmières dans l’élaboration, la mise en œuvre et l’évaluation d’un programme pour la santé des os

  2022cites this paper
• Bone fragility related to breast cancer treatment: The pivotal role of nurses in bone health program development, implementation, and testing.

  2022cites this paper
• Biological and Clinical Aspects of Metastatic Spinal Tumors

  2022cites this paper
• A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors

  2022cites this paper
• Bone diaphysis metastases from the perspective of an orthopedic surgeon – review

  2022cites this paper
• Holistic Approach to the Diagnosis and Treatment of Patients with Tumor Metastases to the Spine

  2022cites this paper
• Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool

  2022cites this paper
• Osteoporosis in Patients With Respiratory Diseases

  2022cites this paper
• Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

  2022cites this paper
• Bone Metastases: From Mechanisms to Treatment.

  2022cites this paper
• MORPHOLOGICAL FEATURES OF TUBULAR BONES REPARATIVE REGENERATION UNDER THE INFLUENCE OF ANTITUMOR CHEMOTHERAPEUTICS.

  2022cites this paper